Are LCTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LCTX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / LCTX / insiders

CABA (33) FATE (35) LXEO (33) IPSC (18) ⌘ Pro Terminal →

Lineage Cell Therapeutics Inc. (LCTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.01 +1.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.01

Lineage Cell Therapeutics Inc. (LCTX) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $252.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LCTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $1.01 (+1.00% 1D, market cap $252.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LCTX ranks #980 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LCTX compare to CABA and FATE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CABA (Cabaletta Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M) and FATE (Fate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $249.2M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LCTX?

▼

Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.01 (-0.01%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LCTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (20/100 Composite)

🔍 WHY LCTX SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.91+6.6% Next Q

Q2 (-2Q)

Grade E$0.97+6.2% Next Q

Q3 (-1Q)

Grade E$1.03-1.9% Next Q

Current

Grade E$1.01-11.8% Hist 90D α

Trajectory: E (15) → E (20)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LCTX currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($1.06) forces dealer call-delta covering toward $2.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 20%NO 80%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LCTX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LCTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LCTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LCTX)

✓Walkthrough of LCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.87%⚡ TESTING RESISTANCE

2026-11-03O $1.03H $1.03L $1.00C $1.01VOL 1.17M

RES: $1.05SUP: $0.75SMA50: $1.01SMA200: $1.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LCTX Butterfly Map → + Track LCTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LCTX)

Health Care Rank #980 of 1016 ⚔️ CABA vs LCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LCTX vs. CABA, FATE, LXEO, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lineage Cell Therapeutics Inc. (LCTX) ranks #980 by composite RQD confidence (20/100, grade E) and #539 by equity capitalization ($252.9M). Within this direct 5-issuer industry benchmark cohort, LCTX leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with LCTX at 20/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LCTX ACTIVE Lineage Cell Therapeutics Inc.	E	20/100	—	—	-35.0%	+1.00%	$252.9M	Benchmark Subject
CABA Cabaletta Bio Inc.	E	33/100	—	—	-35.0%	-5.30%	$256.0M	/caba-vs-lctx →
FATE Fate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-3.36%	$249.2M	/fate-vs-lctx →
LXEO Lexeo Therapeutics Inc.	E	33/100	—	—	-35.0%	-2.55%	$257.6M	/lxeo-vs-lctx →
IPSC Century Therapeutics Inc.	E	18/100	—	—	-14.1%	+0.68%	$266.2M	/ipsc-vs-lctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000876343

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported GAAP revenue of $14.6M (+53.2% vs. FY2024 revenue of $9.5M , and +62.7% cumulative change since FY2023) , GAAP net income of -$63.5M, operating cash flow of -$18.9M, and free cash flow of -$19.4M (+17.8% YoY). On the balance sheet, LCTX closed FY2025 with $112.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.6M	-$63.5M	-$18.9M	-$19.4M	$112.6M	—
FY2024 (FY)	2024-12-31	$9.5M	-$18.6M	-$23.1M	-$23.7M	$113.2M	—
FY2023 (FY)	2023-12-31	$8.9M	-$21.5M	-$28.6M	-$28.6M	—	—

3. LCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LCTX compare to CABA and FATE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LCTX?

Where is LCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

LCTX last traded at $1.01 (+1.00% on volume of 1,722,936 shares), positioning the stock 0.00% above its 50-day simple moving average ($1.01) and -23.48% below its 200-day simple moving average ($1.32). Across its 52-week range of $0.88 to $2.09, LCTX sits at the 10.7% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).

Direct Sub-Reports: LCTX RQD Cockpit LCTX 12M Forecast LCTX Earnings & Move LCTX Dividends & DRIP LCTX Insiders & 13F LCTX Whale Options LCTX Profit Sankey LCTX News & Why

ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LCTX — Lineage Cell Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:39:46Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

LCTX receives an RQD Score of 22, letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine 5/20 (ROIC -35%; FCF yield -7.46%), Whale 13F Flow 8/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 2/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the forensic balance sheet and insider conviction, which the rating treats as the primary risk signals. The strongest relative pillar, institutional flow at 8/20, still sits well below a neutral midpoint. Upside drivers are limited in the source data to the rating's institutional positioning component; the valuation tradeoff is that a $1.03 share price is paired with negative ROIC and negative free-cash-flow yield, leaving little cash-generation support for the equity. The rating's overall message is that the forensic and cash-engine pillars dominate the picture.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lineage Cell Therapeutics Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe its products, customers, or revenue model. The SEC financials show reported revenue of $14. Market capitalization is listed as $0.3B in the profile and $260.5M in market data.

Operating and net losses appear in every reported period, and the FY 2025 net loss of -$63.5M is the largest of the three. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. The Altman Z-Score is 0.2, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $45.8M in FY 2024 to $40.8M in FY 2025 against negative free cash flow in each period.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Institutional whale-flow pillar scores 8/20, the highest of the five RQD pillars. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield -7.46%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $0.88 – $2.09 52-week range.
🐻 Primary Bear Case: Negative ROIC of -35% and a FY 2025 net loss of -$63.5M against $40.8M of cash point to a forensic balance-sheet score of 2/20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care classification and the Biological Products industry label.

Key Question #1: What specific products or revenue streams generate the reported $14.6M in FY 2025 revenue, and who are the customers?
Key Question #2: What was disclosed in the ReSonance Program hearing-loss update that triggered the RED risk-watch classification?
Key Question #3: What is the debt position behind the Debt/Equity ratio of 0.5, given that debt appears as N/A in the reported financials?

LCTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lineage Cell Therapeutics Inc. (LCTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LCTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 20h ago

Lineage Cell Therapeutics, Inc. (LCTX.TA) stock price, news, quote and history

Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

Lineage Cell Therapeutics, Inc. Estimates – AMEX:LCTX

TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call

Benzinga report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Lineage Cell Therapeutics, Inc. (LCTX) Seasonal returns chart

Yahoo Finance UK report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH www.marketscreener.com • 1d ago

Lineage Cell Therapeutics Provides Update On ReSonance Program For Hearing Loss

www.marketscreener.com report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

BIOA Stock Price and Chart — NASDAQ:BIOA

TradingView report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Lineage Provides Update on ReSonance® Program for Hearing Loss

Yahoo Finance report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Athersys, Inc. (ATHXQ) Seasonal Returns Chart

Yahoo! Finance Canada report covering Lineage Cell Therapeutics Inc. (LCTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LCTX Bull vs. Bear Conversation Board — What's Your Call at $1.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LCTX 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.22 (+22.0%)

📌 Pinned Debate

Institutional whale-flow pillar scores 8/20, the highest of the five RQD pillars.

Picked up a starter position in LCTX in my $100K Virtual Cash book at $1.00. Institutional whale-flow pillar scores 8/20, the highest of the five RQD pillars.. Trading inside a $0.88–$2.09 52-week range with -7.46% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.86 (-14.0%)

Spot @ $1.00

Negative ROIC of -35% and a FY 2025 net loss of -$63.5M against $40.8M of cash point to a forensic balance-sheet score of 2/20.

Negative ROIC of -35% and a FY 2025 net loss of -$63.5M against $40.8M of cash point to a forensic balance-sheet score of 2/20.. Look at the math on LCTX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.88 before getting long.